Market Cap
$945.7M
ABUS
Arbutus Biopharma Corp
$4.45 ▼ -2.41%
Prev close $4.56Market cap$945.7M
12-mo target$5.36 (+20.4%)
High Impact Filing (7/10)11 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ABUS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$450.2M
Inst. Activity
11 buys / 10 sells
Social Sentiment
55° Neutral
SEC Reports
9
Press Releases
1
Price chart 30d -13.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 m_and_a
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Ar
Sep 18, 2026 Insider
Beardsley Robert A acquired via exercise 52,533 shares
Director @ $3.20 ($168.1K)
Sep 18, 2026 Insider
Beardsley Robert A acquired via exercise 78,800 shares
Director @ $4.24 ($334.1K)
Sep 18, 2026 Insider
Aug 21, 2026 SEC Beardsley Robert A surrendered for taxes 99,057 shares
Director @ $5.07 ($502.2K)
Arbutus Biopharma announced plans to launch a modified Dutch auction tender offer to repurchase up to $230 million of it
8-K — Impact 7/10
Three asset managers (Fidelity, Russell, Nuveen) added small positions in ABUS during Q2 2026, totaling $2.0M in net buy
INST-CLUSTER — Impact 4/10
Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership reven
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
MORGAN STANLEY — TRIM
17,698,305 shares ($85.0M)
Analyst ratings buy % -3.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | MAINTAIN | Buy | 49% |
| Aug 11, 2025 | Chardan Capital | MAINTAIN | Buy | 49% |
| Mar 28, 2025 | Chardan Capital | MAINTAIN | Buy | 49% |
| Jan 21, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Nov 20, 2024 | Chardan Capital | MAINTAIN | Buy | 49% |
| Nov 18, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Nov 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Nov 7, 2024 | Chardan Capital | MAINTAIN | Buy | 49% |
| Sep 5, 2024 | Jefferies | MAINTAIN | Buy | 53% |
| Aug 2, 2024 | JMP Securities | MAINTAIN | Market Outperform | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Price targets
Where 1 covering analysts think ABUS trades over the next 12 months.
$5.36 +20.4% upside Strong Buy
Current$4.45 Low$5.36 Median$5.36 High$5.36 1 analysts
$5.36$5.36
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +13.6%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
55°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 7 bullish, 0 bearish, 2 mixed, 0 neutral · avg impact 6.4/10.Plus 1 press releases.
BULLISH8-K7/10
Arbutus Biopharma announced plans to launch a modified Dutch auction tender offer to repurchase up t
Aug 21, 2026
MIXEDINST-CLUSTER4/10
Three asset managers (Fidelity, Russell, Nuveen) added small positions in ABUS during Q2 2026, total
Aug 15, 2026
BULLISHPRESS-RELEASE7/10
Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qi
Aug 12, 2026
BULLISH8-K7/10
Arbutus Biopharma reported Q2 2026 results with a net loss of $5.1M ($-0.03 EPS) vs net income of $2
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
m_and_a
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biophar
Sep 30, 2026
m_and_a
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopha
Sep 30, 2026
short_volume
Short Volume: ABUS — 71.7% short (3.7M / 5.1M)
Short: 3,673,931 | Exempt: 3,254 | TRF Vol: 5,125,796 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: ABUS — 64.0% short (2.8M / 4.4M)
Short: 2,815,787 | Exempt: 0 | TRF Vol: 4,398,722 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: ABUS — 64.2% short (2.9M / 4.6M)
Short: 2,939,514 | Exempt: 5 | TRF Vol: 4,577,223 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.03 | $-0.03–$-0.03 | 50.0% | -3.7% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.03 | $-0.03–$-0.03 | -104.1% | -3.7% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $1.03 | $1.03–$1.03 | 540.4% | -0.3% | 1↑ 0↓ | $0.3B | 1 |
| Next FY | $-0.11 | $-0.11–$-0.11 | -110.8% | +10.5% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.028 | — |
| 7d ago | $-0.027 | -0.001 |
| 30d ago | $-0.027 | -0.001 |
| 60d ago | $-0.027 | -0.001 |
| 90d ago | $-0.027 | -0.001 |
Institutional ownership
Which big funds own ABUS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $450.2M total value (93,802,842 shares) as of 2026-Q2. Top holders: MORGAN, BlackRock,, STATE. Net buying activity: 11 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MORGAN STANLEY | 17,698,305 | $85.0M | 18.9% | TRIM -31.6% |
| BlackRock, Inc. | 13,766,071 | $66.1M | 14.7% | — |
| STATE STREET CORP | 7,869,179 | $37.8M | 8.4% | ADD +44.2% |
| Rubric Capital Management LP | 7,532,937 | $36.2M | 8.0% | DOUBLED +320.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,010,679 | $33.7M | 7.5% | — |
| BARCLAYS PLC | 4,207,914 | $20.2M | 4.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,117,691 | $19.8M | 4.4% | — |
| GOLDMAN SACHS GROUP INC | 3,506,802 | $16.8M | 3.7% | DOUBLED +218.7% |
| BANK OF AMERICA CORP /DE/ | 2,646,197 | $12.7M | 2.8% | ADD +57.2% |
| Legal & General Group Plc | 2,466,127 | $11.8M | 2.6% | DOUBLED +1856.1% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 25,891,480 | 17,698,305 | -31.6% | $85.0M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 1,100,434 | 3,506,802 | +218.7% | $16.8M |
| BANK OF AMERICA CORP /DE/ | ADD | 1,683,628 | 2,646,197 | +57.2% | $12.7M |
| Nuveen, LLC | ADD | 259,017 | 496,609 | +91.7% | $2.4M |
| CITADEL ADVISORS LLC | TRIM | 677,138 | 404,696 | -40.2% | $1.9M |
| D. E. Shaw & Co., Inc. | DOUBLED | 143,201 | 381,863 | +166.7% | $1.8M |
| FMR LLC | ADD | 145,126 | 267,188 | +84.1% | $1.3M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 838,210 | 261,052 | -68.9% | $1.3M |
| UBS Group AG | TRIM | 364,471 | 249,208 | -31.6% | $1.2M |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 88,359 | 242,017 | +173.9% | $1.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 18 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Beardsley Robert A | Director | EXERCISE | 52,533 | $3.20 | $168.1K |
| Sep 18, 2026 | Beardsley Robert A | Director | EXERCISE | 78,800 | $4.24 | $334.1K |
| Sep 18, 2026 | Beardsley Robert A | Director | TAX W/H | 99,057 | $5.07 | $502.2K |
| Sep 18, 2026 | Sawhney Roger | Director | EXERCISE | 52,533 | $3.34 | $175.5K |
| Sep 18, 2026 | Sawhney Roger | Director | EXERCISE | 78,800 | $4.24 | $334.1K |
| Sep 18, 2026 | Sawhney Roger | Director | TAX W/H | 100,508 | $5.07 | $509.6K |
| Sep 18, 2026 | Nguyen Tuan | Chief Financial Officer | EXERCISE | 265,625 | $3.49 | $927.0K |
| Sep 18, 2026 | Nguyen Tuan | Chief Financial Officer | EXERCISE | 27,475 | $4.39 | $120.6K |
| Sep 18, 2026 | Nguyen Tuan | Chief Financial Officer | TAX W/H | 206,637 | $5.07 | $1.0M |
| Sep 18, 2026 | Androski Lindsay | President and CEO | EXERCISE | 116,408 | $3.20 | $372.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ABUS.
Shares short
18,484,910
Settlement Sep 15, 2026
Change vs prior
-2.3%
Semi-monthly cycle
Days to cover
5.0
At avg daily volume
Of shares outstanding
≈9.3%
Estimate — not % of float
All ABUS filing & press-release reports (10)
- 8-K reportAug 21, 2026
- INST-CLUSTER reportAug 15, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportAug 12, 2026
- 8-K reportJul 16, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportMay 13, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 23, 2026